VIDEO: Is anastrozole or tamoxifen best for secondary prevention of DCIS?

SAN ANTONIO – Two large phase III randomized trials comparing anastrozole and tamoxifen for prevention of disease recurrence in postmenopausal women with ductal carcinoma in situ were presented at the San Antonio Breast Cancer Symposium.

In an interview, Dr. Anthony Howell, professor of medical oncology at the University of Manchester, England, provides the key take-home lessons from the NSABP B-35 and IBIS-II DCIS trials.

[email protected]

SAN ANTONIO – Two large phase III randomized trials comparing anastrozole and tamoxifen for prevention of disease recurrence in postmenopausal women with ductal carcinoma in situ were presented at the San Antonio Breast Cancer Symposium.

In an interview, Dr. Anthony Howell, professor of medical oncology at the University of Manchester, England, provides the key take-home lessons from the NSABP B-35 and IBIS-II DCIS trials.

[email protected]

SAN ANTONIO – Two large phase III randomized trials comparing anastrozole and tamoxifen for prevention of disease recurrence in postmenopausal women with ductal carcinoma in situ were presented at the San Antonio Breast Cancer Symposium.

In an interview, Dr. Anthony Howell, professor of medical oncology at the University of Manchester, England, provides the key take-home lessons from the NSABP B-35 and IBIS-II DCIS trials.

[email protected]